<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551421</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00241</org_study_id>
    <secondary_id>07-070</secondary_id>
    <secondary_id>U01CA062490</secondary_id>
    <nct_id>NCT00551421</nct_id>
  </id_info>
  <brief_title>Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer</brief_title>
  <official_title>A Phase I/II Trial of Pertuzumab in Combination With Cetuximab and Irinotecan in Previously Treated Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Monoclonal antibodies, such as pertuzumab and cetuximab, can block tumor growth in different
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
      help kill them or carry tumor-killing substances to them. Giving pertuzumab together with
      cetuximab may kill more tumor cells. This phase I/II trial is studying the side effects and
      best dose of pertuzumab when given together with cetuximab and to see how well they work in
      treating patients with previously treated locally advanced or metastatic colorectal cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety, tolerability, and recommended phase II dose of pertuzumab when
      administered in combination with cetuximab in patients with cetuximab-refractory locally
      advanced or metastatic colorectal cancer.

      II. To evaluate the objective tumor response rate (RR) in patients treated with this regimen.

      SECONDARY OBJECTIVES:

      I. To evaluate the median progression-free survival (PFS) of patients treated with this
      regimen.

      II. To evaluate the median overall survival (OS) of patients treated with this regimen.

      III. To evaluate the RR, PFS, and OS in a subgroup of patients who are EGFR-positive by
      immunohistochemistry.

      IV. To explore the relationship between skin rash and the efficacy outcomes of RR, PFS, and
      OS in these patients.

      V. To explore the relationship between objective tumor response on positron emission
      tomography (PET) scan after course two and the efficacy outcomes of RR, PFS, and OS in these
      patients.

      VI. To explore the relationship between a variety of laboratory correlates and the efficacy
      outcomes of RR, PFS, and OS in these patients.

      OUTLINE: This is a multicenter, phase I dose-escalation study of pertuzumab followed by a
      phase II study.

      PHASE I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive
      cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in
      all subsequent courses.

      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

      PHASE II: Patients receive treatment as in phase I. Pertuzumab is administered at the
      recommended phase II dose (determined in phase I). Previously collected tumor tissue samples
      are analyzed for correlative studies. Samples are analyzed for KRAS mutations via polymerase
      chain reaction and pyrosequencing; EGFR expression via immunohistochemistry and fluorescent
      in situ hybridization (FISH); HER receptor and ligand gene expression; and circulating tumor
      cells. Additional blood samples are collected periodically to isolate circulating tumor cells
      and are analyzed via FISH analysis.

      After completion of study treatment, patients are followed at 30 days and then periodically
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recommended Phase II Dose of Pertuzumab When Administered in Combination With Cetuximab (Phase I)</measure>
    <time_frame>28 days</time_frame>
    <description>The regimen was deemed intolerable so there was no recommended phase II dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Tumor Response Rate Defined as the Proportion of Patients With a Best Overall Response of CR or PR, Per RECIST Criteria (Phase II)</measure>
    <time_frame>Best tumor response from time period of start of study treatment to study discontinuation.</time_frame>
    <description>Objective tumor response rate defined as the proportion of patients with a best overall response of CR or PR, per RECIST criteria (Phase II).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>The duration of time from start of study treatment to time of objective disease progression or death.</time_frame>
    <description>The duration of time from start of study treatment to time of objective disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>The duration of time from start of study treatment to death from any cause.</time_frame>
    <description>The duration of time from start of study treatment to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Adenocarcinoma of the Colon</condition>
  <condition>Adenocarcinoma of the Rectum</condition>
  <condition>Recurrent Colon Cancer</condition>
  <condition>Recurrent Rectal Cancer</condition>
  <condition>Stage III Colon Cancer</condition>
  <condition>Stage III Rectal Cancer</condition>
  <condition>Stage IV Colon Cancer</condition>
  <condition>Stage IV Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pertuzumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>2C4 antibody</other_name>
    <other_name>monoclonal antibody 2C4</other_name>
    <other_name>Perjeta</other_name>
    <other_name>rhuMAb-2C4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>C225</other_name>
    <other_name>C225 monoclonal antibody</other_name>
    <other_name>IMC-C225</other_name>
    <other_name>MOAB C225</other_name>
    <other_name>monoclonal antibody C225</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>irinotecan</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluorescence in situ hybridization</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>fluorescence in situ hybridization (FISH)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>gene expression analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mutation analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative study</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a history of colorectal cancer (CRC) treated by surgical resection and
             who develop radiological or clinical evidence of metastatic disease do not require
             separate histological or cytological confirmation of metastatic disease unless 1 of
             the following criteria are met:

               -  More than 5 years has elapsed between the primary surgery and the development of
                  metastatic disease

               -  The primary cancer was stage I

          -  Patients must have representative tumor specimens in paraffin blocks or at least 15
             unstained slides with an associated pathology report obtained at any time prior to
             study entry:

               -  Cytology specimens are not acceptable replacements

          -  Patients must have their tumor tissue screened for KRAS mutation status, and be found
             to have a KRAS wild-type tumor:

               -  No KRAS-mutated tumor

          -  Locally advanced or metastatic disease

          -  Not curable by surgery or amenable to radiotherapy with curative intent

          -  Must have received an cetuximab-containing regimen for at least 6 weeks for treatment
             of metastatic disease

          -  Documented progression of disease or intolerable toxicity during or within 3 months of
             receiving this regimen

          -  Patients who have received an cetuximab-containing regimen as adjuvant therapy for
             resected stage II or III CRC are eligible provided recurrent disease is documented &lt; 6
             months after completion of adjuvant treatment

          -  Must have received &gt;= 1 prior chemotherapeutic regimen for treatment of metastatic
             disease with any of the following:

               -  Cetuximab

               -  Must have resolution of any skin rash related to prior treatment with cetuximab

               -  No prior cetuximab which required a dose reduction for toxicity

               -  5-fluorouracil or capecitabine

               -  Irinotecan hydrochloride or oxaliplatin

          -  Measurable disease by CT scan or physical exam

          -  ECOG performance status (PS) 0-1 (Karnofsky PS 70-100%)

          -  Life expectancy &gt; 12 weeks

          -  Absolute neutrophil count &gt;= 1,500/mcL

          -  Platelet count &gt;= 100,000/mcL

          -  Leukocytes &gt;= 3,000/mcL

          -  Hemoglobin &gt;= 9 g/dL (transfusion, erythropoietin, or other approved hematopoietic
             growth factors allowed)

          -  Total bilirubin =&lt; 1.5 times upper limit of normal (ULN)

          -  AST and ALT =&lt; 5 times ULN

          -  Creatinine normal OR Creatinine clearance &gt;= 60 mL/min

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception prior to and during study therapy

          -  Cardiac left ventricular ejection fraction &gt;= 50% OR &gt;= lower limit of normal

          -  No evidence of left ventricular wall motion abnormalities as measured by ECHO or MUGA
             scan

          -  None of the following cardiac conditions:

               -  Uncontrolled high blood pressure

               -  Unstable angina

               -  Symptomatic congestive heart failure

               -  Congestive heart failure, cardiac dysfunction, or cardiomyopathy requiring
                  medication treatment

               -  Myocardial infarction within the past 6 months

               -  Serious uncontrolled cardiac arrhythmia

               -  New York Heart Association class III or IV heart disease

          -  No active or uncontrolled infection

          -  No predisposing colonic or small bowel disorders in which the symptoms are
             uncontrolled as indicated by baseline pattern of &gt; 3 loose stools/day (in patients
             without a colostomy or ileostomy)

          -  Patients with a colostomy or ileostomy may be eligible at investigator discretion

          -  No psychiatric illness/social situation that would limit compliance with study
             requirements

          -  No other prior or concurrent malignancy, except for adequately treated basal cell or
             squamous cell skin cancer, in situ carcinoma of the cervix, lobular carcinoma in situ
             in one breast, or other cancer from which the patient has been disease-free for at
             least 5 years

          -  No other medical or psychiatric disease, metabolic dysfunction, physical examination
             finding, or clinical laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicates the use of an investigational drug or that may affect
             the interpretation of the study results or render the patient at high risk for
             treatment complications

          -  No history of allergic reactions, hypersensitivity, or intolerance to cetuximab,
             and/or compounds of similar chemical or biologic composition to pertuzumab or
             cetuximab (i.e., other monoclonal antibodies such as bevacizumab) that led to
             discontinuation of the drug

          -  Patients able to tolerate subsequent infusions after a reaction are eligible

          -  At least 4 weeks since prior major surgery (e.g., laparotomy) and recovered (Insertion
             of a vascular access device is not considered major or minor surgery)

          -  At least 2 weeks since prior minor surgery and recovered (Insertion of a vascular
             access device is not considered major or minor surgery)

          -  At least 4 weeks since prior major radiotherapy (e.g., chest or bone palliative
             radiotherapy)

          -  At least 4 weeks since prior bevacizumab

          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
             and recovered

          -  No prior agents directed against EGFR and/or HER2

          -  No more than one prior treatment regimen for metastatic disease; Prior chemotherapy in
             the adjuvant setting following resection of stage II or III disease allowed provided
             the regimen did not contain irinotecan hydrochloride and/or an agent directed against
             EGFR and/or HER2

          -  No prior doxorubicin or liposomal doxorubicin at doses &gt; 360 mg/m^2; epirubicin at
             doses &gt; 720 mg/m^2; mitoxantrone at doses &gt; 120 mg/m^2; or idarubicin at doses &gt; 90
             mg/m^2

          -  No prior radiotherapy to &gt; 15% of the bone marrow

          -  No prior standard adjuvant chemoradiotherapy for rectal cancer

          -  No phenytoin, phenobarbital, carbamazepine, or any other enzyme-inducing
             anti-convulsant drugs (EIACDs) for at least 7 days before, during, and for 7 days
             after the final dose of irinotecan hydrochloride

          -  Concurrent gabapentin or other non-EIACDs are allowed

          -  No St. John's wort for at least 14 days before, during, and for 7 days after the final
             dose of irinotecan hydrochloride

          -  No concurrent corticosteroids, except for stable doses of prednisone (&lt; 20 mg/day or
             equivalent), topical or inhaled corticosteroids, or corticosteroids for reasons
             unrelated to treatment of colorectal cancer

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) for any of the following
             reasons:

               -  To avoid dose reductions or delays

               -  Prophylactic treatment

               -  Treatment of febrile neutropenia

          -  No other concurrent HER family-targeted therapy

          -  No concurrent rifampin

          -  No concurrent herbal remedies unless initiated prior to study entry

          -  No other concurrent investigational agents

          -  No other concurrent anticancer therapy, including cytotoxic chemotherapy,
             radiotherapy, immunotherapy, hormonal therapy, or biological anticancer therapy

          -  Histologically or cytologically confirmed adenocarcinoma of the colon or rectum

          -  Site of the primary lesion must be or have been confirmed endoscopically,
             radiologically, or surgically to be or have been in the large bowel

          -  No known brain metastases

          -  No concurrent fluconazole
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimmie Ng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2007</study_first_submitted>
  <study_first_submitted_qc>October 30, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2007</study_first_posted>
  <results_first_submitted>December 17, 2014</results_first_submitted>
  <results_first_submitted_qc>February 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2015</results_first_posted>
  <last_update_submitted>March 11, 2015</last_update_submitted>
  <last_update_submitted_qc>March 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>3 patients were enrolled into the original protocol between 11/07 and 05/08. 1 subject developed Grade 3 diarrhea, all 3 subjects experienced significant skin toxicity. The protocol was therefore amended to recruit cetuximab-refractory mCRC patients only. 14 patients were enrolled in this part of the study between 03/09 and 07/10 at 6 US centers.</recruitment_details>
      <pre_assignment_details>One patient enrolled into the amended part of the protocol withdrew consent prior to receiving any study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pertuzumab and Cetuximab</title>
          <description>Original Protocol, Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1 of each cycle (loading dose cycle 1 only). Patients also receive cetuximab IV over 60-120 minutes on days 2 (loading dose only), 8, and 15 of cycle 1 and on days 1, 8, and 15 in all subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Amended Protocol, Phase I: Same as Original Protocol (see above) without a loading dose of Cetuximab (maintenance dose given on cycle 1, day 2 instead).
Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I).
Given IV: irinotecan hydrochloride, pertuzumab, cetuximab
Correlative Studies: laboratory biomarker analysis, gene expression analysis, fluorescence in situ hybridization, mutation analysis, polymerase chain reaction, immunohistochemistry staining method</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Original Protocol, Dose Level 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3">1 subject developed Grade 3 diarrhea, all 3 subjects experienced significant skin toxicity.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Amended Protocol (Cetuximab-refr. mCRC)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pertuzumab and Cetuximab</title>
          <description>Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" lower_limit="46" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Recommended Phase II Dose of Pertuzumab When Administered in Combination With Cetuximab (Phase I)</title>
        <description>The regimen was deemed intolerable so there was no recommended phase II dose.</description>
        <time_frame>28 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pertuzumab and Cetuximab</title>
            <description>Original Protocol, Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1 of each cycle (loading dose cycle 1 only). Patients also receive cetuximab IV over 60-120 minutes on days 2 (loading dose only), 8, and 15 of cycle 1 and on days 1, 8, and 15 in all subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Amended Protocol, Phase I: Same as Original Protocol (see above) without a loading dose of Cetuximab (maintenance dose given on cycle 1, day 2 instead).
Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I).
Given IV: irinotecan hydrochloride, pertuzumab, cetuximab
Correlative Studies: laboratory biomarker analysis, gene expression analysis, fluorescence in situ hybridization, mutation analysis, polymerase chain reaction, immunohistochemistry staining method</description>
          </group>
        </group_list>
        <measure>
          <title>Recommended Phase II Dose of Pertuzumab When Administered in Combination With Cetuximab (Phase I)</title>
          <description>The regimen was deemed intolerable so there was no recommended phase II dose.</description>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The regimen was deemed intolerable so there was no recommended phase II dose.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Tumor Response Rate Defined as the Proportion of Patients With a Best Overall Response of CR or PR, Per RECIST Criteria (Phase II)</title>
        <description>Objective tumor response rate defined as the proportion of patients with a best overall response of CR or PR, per RECIST criteria (Phase II).</description>
        <time_frame>Best tumor response from time period of start of study treatment to study discontinuation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I).
pertuzumab: Given IV
cetuximab: Given IV
irinotecan hydrochloride: Given IV
immunohistochemistry staining method: Correlative study
fluorescence in situ hybridization: Correlative study
gene expression analysis: Correlative study
mutation analysis: Correlative study
polymerase chain reaction: Correlative study
laboratory biomarker analysis: Correlative study</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Tumor Response Rate Defined as the Proportion of Patients With a Best Overall Response of CR or PR, Per RECIST Criteria (Phase II)</title>
          <description>Objective tumor response rate defined as the proportion of patients with a best overall response of CR or PR, per RECIST criteria (Phase II).</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Best Response of Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Best Response of Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <description>The duration of time from start of study treatment to time of objective disease progression or death.</description>
        <time_frame>The duration of time from start of study treatment to time of objective disease progression or death.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I).
pertuzumab: Given IV
cetuximab: Given IV
irinotecan hydrochloride: Given IV
immunohistochemistry staining method: Correlative study
fluorescence in situ hybridization: Correlative study
gene expression analysis: Correlative study
mutation analysis: Correlative study
polymerase chain reaction: Correlative study
laboratory biomarker analysis: Correlative study</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <description>The duration of time from start of study treatment to time of objective disease progression or death.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.5" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The duration of time from start of study treatment to death from any cause.</description>
        <time_frame>The duration of time from start of study treatment to death from any cause.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Phase I: Patients receive pertuzumab IV over 30-60 minutes on day 1. Patients also receive cetuximab IV over 60-120 minutes on days 2, 8, and 15 of course 1 and on days 1, 8, and 15 in all subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I).
pertuzumab: Given IV
cetuximab: Given IV
irinotecan hydrochloride: Given IV
immunohistochemistry staining method: Correlative study
fluorescence in situ hybridization: Correlative study
gene expression analysis: Correlative study
mutation analysis: Correlative study
polymerase chain reaction: Correlative study
laboratory biomarker analysis: Correlative study</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The duration of time from start of study treatment to death from any cause.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.6" upper_limit="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event information was collected between November 2007 and October 2010.</time_frame>
      <desc>3 patients were enrolled to Dose Level 1. 1 subject developed gr. 3 diarrhea (hospitalized), and skin toxicity was seen among the 3 subjects. The study was amended and the loading dose of cetuximab was eliminated. We report the adverse event results of the subjects enrolled on the original and the amended protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>Pertuzumab and Cetuximab</title>
          <description>Original Protocol: Patients received pertuzumab IV over 30-60 minutes on day 1 of each cycle (loading dose on cycle 1, day 1 only). Patients also receive cetuximab IV over 60-120 minutes on days 2 (loading dose), 8, and 15 of cycle 1 and on days 1, 8, and 15 in all subsequent cycles. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Amended Protocol, Phase I: Same as the Original Protocol (see above) except the Cetuximab loading dose was no longer given on cycle 1, day 2 (maintainance dose given).
Phase II: Patients receive treatment as in phase I. Pertuzumab is administered at the recommended phase II dose (determined in phase I).
Given IV: pertuzumab, cetuximab, irinotecan hydrochloride
Corrlateive studies: immunohistochemistry staining method, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, laboratory biomarker analysis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiac ischemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>troponin elevation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>small bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>mucositis or stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST elevation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>acneiform rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>skin pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eyelid dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>blurry vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>ocular (other)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>distension/bloating</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>mucositis or stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>gastrointestinal (other)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>fever without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>weakness (non-neuropathic)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>colitis - infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>infection (other)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT elevation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>AST elevation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>alkaline phosphatase elevation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hepatic (other)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>INR elevation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>PTT prolongation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>metabolic/lab (other)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>neuropathy (sensory)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>neurologic (other)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>incontinence - urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal discharge</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>acneiform rash</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>edema of head and neck</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>edema of limb</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>edema trunk/genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>lymphedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>nail changes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>pruritis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>skin (other)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Combination intolerable due to overlapping toxicities of diarrhea, rash and mucositis; a unique rash with desquamation seen in most patients across all dose levels. Correlative study inconclusive with too few patients and timepoints with results.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kimmie Ng</name_or_title>
      <organization>Dana-Farber Cancer Institute</organization>
      <phone>617-632-4150</phone>
      <email>kimmie_ng@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

